◆英語タイトル:GenKyoTex SA (GKTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7976
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
GenKyoTex SA (GenKyoTex), formerly Genticel SA, is a biopharmaceutical company that develops NOX therapies. The company develops targeted NOX inhibitors and molecule therapeutics that inhibit the NOX family of enzymes. GenKyoTex’s lead product candidate, GKT831, a selective NOX1/4 inhibitor, is in phase II clinical trial in primary biliary cholangitis, type 1 diabetes and kidney disease, and idiopathic pulmonary fibrosis. Its second product candidate, GKT771, currently under preclinical testing, is a NOX1 inhibitor that targets multiple pathways in angiogenesis, pain processing, and inflammation. The company’s products are used in the treatment of diabetic nephropathy. The company has operations in Switzerland and France. GenKyoTex is headquartered in Saint-Julien- en-Genevois, France.
GenKyoTex SA (GKTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GenKyoTex SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
GenKyoTex SA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
GenKyoTex Raises USD21 Million in Series D Financing 11
GenKyoTex Raises US$26 Million In Extended Series C Financing 13
Merger 15
Genticel Merges with GenKyoTex 15
Licensing Agreements 17
Serum Institute Expands Licensing Agreement with Genkyotex 17
Equity Offering 18
GenKyoTex Plans to Raise Funds through IPO 18
Debt Offering 19
Genkyotex to Raise USD5.7 Million in Private Placement of 15% First Tranche Notes Due 2019 19
GenKyoTex SA – Key Competitors 21
GenKyoTex SA – Key Employees 22
GenKyoTex SA – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Sep 26, 2018: Genkyotex reports first-half 2018 financial results 24
Feb 28, 2018: Genkyotex Reports 2017 Financial Results 26
Oct 26, 2017: Genkyotex Provides Business Update for Q3 2017 28
Sep 21, 2017: Genkyotex Announces 2017 First-Half Financial Results 29
Apr 27, 2017: Genkyotex Provides Business Update for Q1 2017 30
Product News 31
10/26/2017: Genkyotex Provides Business Update For Q3 2017 31
Clinical Trials 32
May 07, 2018: Genkyotex Announces Positive Outcome from Independent SMB’s First Pre-Planned Review of GKT831′s Phase 2 Trial in Primary Biliary Cholangitis 32
Aug 03, 2017: Genkyotex’s GKT831 Shown to Delay Tumor Growth in Multiple Preclinical Models by Targeting Cancer Associated Fibroblasts 33
Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis 34
May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis 35
Other Significant Developments 36
Apr 25, 2018: Genkyotex Reports March 31, 2018 Cash Position and Provides Business Update 36
Jan 31, 2018: Genkyotex Reports December 31, 2017 Cash Position and Provides Business Update 37
Jul 27, 2017: Genkyotex Provides Business Update for Q2 2017 38
Jun 05, 2017: Edison Issues Outlook on Genkyotex 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Tables
GenKyoTex SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GenKyoTex SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GenKyoTex SA, Deals By Therapy Area, 2012 to YTD 2018 9
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
GenKyoTex Raises USD21 Million in Series D Financing 11
GenKyoTex Raises US$26 Million In Extended Series C Financing 13
Genticel Merges with GenKyoTex 15
Serum Institute Expands Licensing Agreement with Genkyotex 17
GenKyoTex Plans to Raise Funds through IPO 18
Genkyotex to Raise USD5.7 Million in Private Placement of 15% First Tranche Notes Due 2019 19
GenKyoTex SA, Key Competitors 21
GenKyoTex SA, Key Employees 22
GenKyoTex SA, Subsidiaries 23
List of Figures
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GenKyoTex SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9